Biotechnology Common Tools Presentation on Shared Facilities Turin, 19th February 2010

1. Biotechnology Common Tools Presentation on Shared Facilities Turin, 19th February 2010 Service and Support for Biotechnology in Berlin-Brandenburg

2. Agenda • Regional Sharing: Opportunities and restraints • Sharing on Campus Berlin-Buch: Research-Clinics-Biotech • Example of sharing practice: FMP Screening Unit

3. Opportunities for sharing in Berlin-Brandenburg

4. Regional Biotechnology Parks BioTechnologieZentrum Hennigsdorf Campus Berlin-Buch Berlin Adlershof berlinbiotechpark Biotechnologiepark Luckenwalde Potsdam Biotech Campus

5. Identified (large-scale) Facilities

6. Agenda • Regional Sharing: Opportunities and restraints • Sharing on Campus Berlin-Buch: Research-Clinics-Biotech • Example of sharing practice: FMP Screening Unit

7. Campus Berlin-Buch • A modern science, health and biotechnology park with a clear focus on biomedicine and 2,200 employees on 32 hectares • Unique environment for scientific exchange and research collaboration, facilitated by the close physical proximity of • research institutes • clinics • biotechnology companies • Major areas of activity include • study of the molecular causes of cancer • cardiovascular and neurodegenerative diseases • interdisciplinary basic research to develop new drugs • patient-oriented clinical research • commercial realization of biomedical insights • Investments of more than 200 million euros from the federal government, state government and the EU Innovative location with an attractive infrastructure and international flair

8. Concept • High quality of living and working • closeness of the institutions to each other • setting in a beautiful park landscape • communicative places to eat, guesthouses, kindergarten, research library • synergy between science and art with sculpture park, exhibitions and a museum • Health Region • fast connection to Berlin‘s cultural life • direct proximity to the lakes and forests provides numerous opportunities for leisure and recreation • Communication & Information • Max Delbrück Communications Center • one of the most modern congress centers in Berlin • serves as an international meeting place for researchers and physicians as well as an arena for active social discourse • CampusInfoCenter • Located in the same historic building as the Life Science Learning Lab • popular with visitors and guests of the Campus as a place to meet and obtain information • Events • „Long Night of the Sciences“ • In June welcomes thousands of visitors annually • gives insight into the biosciences and medicine in an entertaining way through participatory courses, lab tours, "science comedy" and information booths

9. Structure and on-site facilities Basic Research Institutes • Max Delbrück Center for Molecular Medicine (MDC) • Leibniz Institute for Molecular Pharmacology (FMP) Clinical Research Institutes • Robert Rössle Clinic for Tumor Diseases (RRK) • Franz Volhard Clinic for Cardiovascular Deseases (FVK) Outstanding innovation and growth potential through value-creating synergies Maximum-care clinics • HELIOS Clinic Berlin-Buch • Evangelische Lungenklinik Berlin (ELK) • Rheuma Clinic Berlin-Buch • All organized as private-enterprise entities BiotechPark • Approximately 40 companies in 2009 • Amongst others Silence Therapeutics, Glycotope, ImaGenes, Invitek, Bavarian Nordic

10. Research Institutes: MDC & FMP

11. Biotech Park Infrastructure • Approximately 26,000 m² of sector-specific lab and office space is available to founders and companies under attractive conditions • Additional sites for building on the Campus offer options for development over the middle and long term • A tradition of excellence in molecular medical basic research and clinical research as well outstanding maximum care for patients make the BiotechPark Berlin an ideal environment • The creative atmosphere of the Campus promotes know-how exchange, technology transfer and joint projects • Managed by BBB Managment GmbH Campus Berlin-Buch being responsible for coordinating the development of the entire site Companies • At present approximately 47 biotechnology companies are located on the Campus with a total of 750 employees • The spectrum of business fields includes • medical-technical products • molecular diagnostics and therapies • preclinical pharmacological and pharmacogenomics tests • RNA technologies • the search for pharma-relevant target molecules • production and testing of drugs under the specifications of (GMP) • analysis and synthesis of biomolecules

12. Proximity of facilities HELIOS Genomhaus (FMP & MDC) BiotechPark FMP MDC

13. Agenda • Regional Sharing: Opportunities and restraints • Sharing on Campus Berlin-Buch: Research-Clinics-Biotech • Example of sharing practice: FMP Screening Unit

14. The Leibniz Institute for Molecular Pharmacology (FMP) Facts & figures • 258 staff (08/08) • 163 research scientists • Budget 2008: 19 Mio Euro • 5.8 Mio Euro external funding (total in 2008) Research sections & focus • Sections: Chemical Biology, Structural Biology, Signal Transduction/ Molecular Genetics • Focus: • Structure and function of proteins • New approaches to modulating protein function • Identification of small molecules as chemical, diagnostic and therapeutic tools • Identification of biological macromolecules as drug targets Mission • Scientific Mission: • 40.000 currently available drugs act through 324 structures (proteins) • Up to 10.000 structures are considered drug targets (proteins) • Goal: broaden the basis of drug therapy! • Organisational Mission: • Improve conditions for drug-related research and drug development by • promoting interdisciplinary projects that combine chemical biological approaches (Chemical Biology) • establishing drug discovery and development networks (public-private partnerships, national and international scale)

15. Screening at the FMP Screening Unit Open Access HTS Automatic Microscope Screening Robot • Projects on not (yet) validated targets • Development of chemical toos for the investigation of protein functions, diagnostic substances and drugs • Open platform for academic partners and SME

16. Featured technologies of screening unit in silico screening Process Automation unique technologies Screening Unit Open Access HTS LabChip online database compound libraries Automated microscopes

17. Sharing of screening facility Open Access Screening Platform (> 80 projects since 2004) Yale University, Craig Crews University of Oxford, S. Knapp MRC Cambridge, E. Gherardi & T. Blundel University of Glasgow, E. Munroe Biotechnology Center Oslo, Kjetil Tasken University of Oslo, S. Strauss Karolynska Institute, S. Strömblad University Göteborg, S. Trybala Vanderbilt University, M. Waterman UCSF, L. Podust EMBL-Hamburg, M. Willmanns MPI-Dortmund, C. Ottmann Max-Planck-Group Hamburg, E. Mandelkow Max-Planck-Group Hamburg, H. Bartunik ZMNH Hamburg, M. Schachner TU München, J. Ruland Universität Leipzig, M. Schäfer Universität Frankfurt, R. Stauber Universität Rostock, Thiesen Universitätsklinik Marburg, T. Gress Bayer Schering Pharma, A. Sommer NDDI (Novartis, Boston, G. Petrella) Wnt-antagonists: Metastasis

18. European screening activities EU-OPENSCREEN • A European Infrastructure of Open Screening Platforms for Chemical Biology • A distributed infrastructure open for transnational access • Will be used by researchers from universities and research institutes who have either only limited in-house facilities or no access at all to such an infrastructure • Will accelerate the generation of knowledge on the bioactivities of chemicals as well as on the responses of biological systems • Unlike commercial screening platforms and pharmaceutical industry EU-OPENSCREEN will address non-validated targets

19. EU-OPENSCREEN network* 2 1 16 15 14 3 13 12 5 11 6 4 8 7 10 17 9 Coordination Centre at FMP Berlin Sweden – Univ. Umeå Finland – FIMM Nordic EMBL Helsinki Poland – IMB, Lodz Hungary – Univ. Budapest Czech Rep. – Inst. Molecular Genetics Prague Austria – CeMM Wien Italy – CISI Milano Switzerland – EcolePolytechn. Féd. Lausanne Spain – Barcelona Science Parc, Portugal – Univ. Lisbon France – Univ. Strasbourg Netherlands – NKI Amsterdam European Bioinformatics Institute (EBI) UK – Univ. Dundee,Univ. Cambridge Denmark – Univ. Copenhagen Norway – Univ. of Oslo Greece – BRFAA Athens *Important remark: This list shows the current network, which is not necessarily identical with the institutions participating in the PP.

20. Contact Details Thank you for your attention! Wolfgang Korek BioTOP Berlin-Brandenburg Fasanenstraße 85 10623 Berlin Tel: + 49 30 3186-2218 korek@biotop.de www.biotop.de